by barry101 | Nov 13, 2020 | Press Releases
HOUSTON, Nov. 13, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced its financial results...
by barry101 | Oct 29, 2020 | Press Releases
Initial information sharing agreement signed to further research into the anti-viral potential of WP1122HOUSTON, Oct. 29, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical...
by barry101 | Oct 27, 2020 | Press Releases
HOUSTON, Oct. 27, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced...
by barry101 | Oct 21, 2020 | Press Releases
Annamycin demonstrated up to 30-fold greater concentration in lungs of Annamycin than the current standard of care drug; enables targeting cancer in its sanctuary siteHOUSTON, Oct. 21, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a...
by barry101 | Oct 13, 2020 | Press Releases
Adult brain tumor trial advances to final dose escalation cohort of WP1066 HOUSTON, Oct. 13, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting...
by barry101 | Oct 6, 2020 | Press Releases
Also shows activity in Zika and Dengue FeverHOUSTON, Oct. 6, 2020 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the...
